Immunogenicity of constitutively active V599EBRaf

• Verfasst von: Andersen, Mads Hald [VerfasserIn]
• Verfasst von: Ugurel, Selma [VerfasserIn]
• Verfasst von: Schadendorf, Dirk [VerfasserIn]
• Titel: Immunogenicity of constitutively active V599EBRaf
• Verf.angabe: Mads Hald Andersen, Joachim Fensterle, Selma Ugurel, Sine Reker, Roland Houben, Per Guldberg, Thomas G. Berger, Dirk Schadendorf, Uwe Trefzer, Eva-B. Bröcker, Per thor Straten, Ulf R. Rapp, and Jürgen C. Becker
• E-Jahr: 2004
• Jahr: August 2, 2004
• Umfang: 5 S.
• Fussnoten: Gesehen am 10.12.2020 ; Im Titel ist der Ausdruck "V599E" hochgestellt
• Titel Quelle: Enthalten in: Cancer research
• Ort Quelle: Philadelphia, Pa. : AACR, 1916
• Jahr Quelle: 2004
• Band/Heft Quelle: 64(2004), 15, Seite 5456-5460
• ISSN Quelle: 1538-7445
• DOI: doi:10.1158/0008-5472.CAN-04-0937
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1742485235

Abstract

Activating BRAF somatic missense mutations within the kinase domain are present in 60-66% of melanomas. The vast majority of these represent a single substitution of glutamate for valine (V599E). Here, we demonstrate spontaneous HLA-B*2705-restricted cytotoxic T-cell responses against an epitope derived from V599EBRaf. These T-cell responses were mutation specific as the corresponding epitope derived from wild-type BRaf was not recognized. The loss of the V599EBRAF genotype during progression from primary to metastatic melanoma in patients with V599EBRaf specific T-cell responses suggests an active immune selection of nonmutated melanoma clones by the tumor-bearing host.